Prudential Financial
PLX icon

Prudential Financial’s Protalix BioTherapeutics PLX Stock Holding History

Prudential Financial’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.9K Buy
+10,110
New +$25.1K ﹤0.01% 2374
2025
Q2 		– Sell
-36,400
Closed -$93.2K – 2493
2025
Q1 		$93.2K Hold
36,400
– – ﹤0.01% 2136
2024
Q4 		$68.4K Buy
+36,400
New +$51.5K ﹤0.01% 2181

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prudential Financial's PLX Position: Q1 2026 in Review

Prudential Financial opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 10,110 shares worth $21.9K. The stake represents ﹤0.01% of the portfolio and ranks #2374 among its holdings. This is a return to the name: Prudential Financial previously reported a position in PLX as recently as Q1 2025.

Prudential Financial first reported a position in PLX in Q4 2024 and has held it in 3 quarters since. The position peaked at $93.2K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Prudential Financial held 10,110 shares of Protalix BioTherapeutics worth $21.9K as of Q1 2026.
  • Protalix BioTherapeutics was a new Prudential Financial position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2374 holding.
  • Prudential Financial first reported a position in Protalix BioTherapeutics in Q4 2024 and has held it in 3 quarters since.
  • Prudential Financial's Protalix BioTherapeutics position peaked at $93.2K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.